Alnylam: Q3 Earnings Snapshot

Alnylam Pharmaceuticals, a Cambridge-based company, reported a significant turnaround in its third quarter, with a net income of $251.1 million, beating analyst expectations. The company's earnings per share rose to $2.90, and revenue reached $1.25 billion, also surpassing predictions. Alnylam's focus on RNA interference drugs has drawn attention in the biotech world, and its strong performance has led to a 69% stock increase over the past year. Investors are eager to see what the company does next, given its promising results.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.